SCHEMBL4928718

SCHEMBL4928718

CCOc1ccc(Nc2c(Cl)cccc2[N+](=O)[O-])cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.51
▸ MEN1 O00255 4/20 0.51
▸ NPC1 O15118 4/20 0.51
▸ RAB9A P51151 4/20 0.51
▸ MAPT P10636 12/20 0.47
▸ MAPK1 P28482 4/20 0.47
▸ ALDH1A1 P00352 3/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ RECQL P46063 1/20 0.44
▸ POLB P06746 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ OPRM1 P35372 1/20 0.44
▸ OPRD1 P41143 1/20 0.44
▸ RAD52 P43351 1/20 0.44
▸ NFKB1 P19838 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ USP2 O75604 1/20 0.43
▸ SLC2A1 P11166 1/20 0.43
▸ HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14463471 0.82 KMT2A (0.49) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL10647647 0.80 KMT2A (0.49) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL9995024 0.79 CXCR2 (0.58) KMT2AMEN1MAPTMAPK1ALDH1A1
SCHEMBL5838060 0.79 MAPK1 (0.62) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL9994948 0.78 CXCR2 (0.45) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL4931104 0.78 MAPT (0.58) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL4930501 0.77 MAPT (0.49) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL1625430 0.75 TSHR (0.45) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL4932353 0.74 MEN1 (0.60) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL10656462 0.74 MAPT (0.47) KMT2AMEN1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 — — US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 — — US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 — — US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 KMT2A 1963/4885MEN1 4097/4885NPC1 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback